NCT06834438
Gene Therapy for Neurofibromatosis Type 2 (NF2) With ST002
StatusCompleted
PhaseNot applicable
Primary completion
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 15 words Show 5 more changesShow less
- Completed without a posted recruiting period
- Primary completion date changed from estimate of Feb 1, 2026 to Apr 8, 2026
- Study completion date changed from estimate of Feb 1, 2027 to Apr 13, 2026
- Start date changed from estimate of Feb 15, 2025 to Mar 19, 2025
- Secondary endpoints: details revised at 1 of 2 entries
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Safety evaluation
Timeframe: From baseline to Week 24 after administration
Secondary (1)
Efficacy evaluation
Arms and interventions
ST002Experimental
Subjects will receive with a single multi-point intra-tumoral injection of ST002 from 1x10\^7 to 1x10\^8 TU into the tumor.
Genetic: ST002
Sites
1 site in 1 country
- Shuhang WangBeijing, Beijing Municipality, China